

Cemiplimab EMPOWER-Lung 1

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Cemiplimab EMPOWER-Lung 1

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC

Experimental Arm: Cemiplimab

Control Arm: Platinum based ChT (Crossover allowed)

